BioPharmX Corporation Appoints Michael Hubbard To
Post# of 223
Posted On: 01/28/2015 2:52:47 PM
BioPharmX Corporation Appoints Michael Hubbard To Its Board Of Directors
MENLO PARK, Calif., Jan. 28, 2015 /PRNewswire/ -- BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Michael Hubbard as a new independent member of its board of directors. Hubbard, a seasoned financial executive with a career in public accounting and auditing, will also lead the company's audit committee. Hubbard's appointment brings the board's total number of members to four.
"We are delighted with Mike's decision to join BioPharmX's board of directors," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX. "His breadth and depth of experience serving companies of all sizes from venture-backed to Fortune 500 entities and across several sectors – including life sciences – will be invaluable as we continue to position BioPharmX for growth."
Throughout his career Hubbard had served as a senior audit partner − at Deloitte & Touche LLP prior to retiring and also at PricewaterhouseCoopers LLP. In these roles he served private and publicly held clients across the life sciences, waste management, construction, and technology sectors, advising domestic and international issuer companies on complex transactions, including 19 IPOs and numerous follow-on equity and debt offerings. Hubbard holds a B.A. degree in Business Administration with a concentration in Accounting and an MBA degree from Washington State University. He is a licensed CPA in the states of Washington and California and is a certified (by Deloitte & Touche LLP) practitioner of international financial reporting standards.
MENLO PARK, Calif., Jan. 28, 2015 /PRNewswire/ -- BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Michael Hubbard as a new independent member of its board of directors. Hubbard, a seasoned financial executive with a career in public accounting and auditing, will also lead the company's audit committee. Hubbard's appointment brings the board's total number of members to four.
"We are delighted with Mike's decision to join BioPharmX's board of directors," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX. "His breadth and depth of experience serving companies of all sizes from venture-backed to Fortune 500 entities and across several sectors – including life sciences – will be invaluable as we continue to position BioPharmX for growth."
Throughout his career Hubbard had served as a senior audit partner − at Deloitte & Touche LLP prior to retiring and also at PricewaterhouseCoopers LLP. In these roles he served private and publicly held clients across the life sciences, waste management, construction, and technology sectors, advising domestic and international issuer companies on complex transactions, including 19 IPOs and numerous follow-on equity and debt offerings. Hubbard holds a B.A. degree in Business Administration with a concentration in Accounting and an MBA degree from Washington State University. He is a licensed CPA in the states of Washington and California and is a certified (by Deloitte & Touche LLP) practitioner of international financial reporting standards.
(0)
(0)BioPharmX Corporation (BPMX) Stock Research Links
Scroll down for more posts ▼